We are upgrading the repository! A content freeze is in effect until November 22nd, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.
Repeated Administration of 2-Hydroxypropyl-β-Cyclodextrin (HPβCD) Attenuates the Chronic Inflammatory Response to Experimental Stroke
Author
Becktel, D.A.Zbesko, J.C.
Frye, J.B.
Chung, A.G.
Hayes, M.
Calderon, K.
Grover, J.W.
Li, A.
Garcia, F.G.
Tavera-Garcia, M.A.
Schnellmann, R.G.
Wu, H.-J.J.
Nguyen, T.-V.V.
Doyle, K.P.
Affiliation
Department of Immunobiology, University of ArizonaDepartment of Molecular and Cellular Biology, University of Arizona
Arizona Arthritis Center, University of Arizona
Department of Pharmacology and Toxicology, University of Arizona
Department of Neurology, University of Arizona
BIO5 Institute, University of Arizona
Arizona Center on Aging, University of Arizona
Department of Psychology, University of Arizona Department of Neurosurgery, University of Arizona
Issue Date
2022
Metadata
Show full item recordPublisher
Society for NeuroscienceCitation
Becktel, D. A., Zbesko, J. C., Frye, J. B., Chung, A. G., Hayes, M., Calderon, K., Grover, J. W., Li, A., Garcia, F. G., Tavera-Garcia, M. A., Schnellmann, R. G., Wu, H.-J. J., Nguyen, T.-V. V., & Doyle, K. P. (2022). Repeated Administration of 2-Hydroxypropyl-β-Cyclodextrin (HPβCD) Attenuates the Chronic Inflammatory Response to Experimental Stroke. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience.Rights
Copyright © 2022 Becktel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Globally, more than 67 million people are living with the effects of ischemic stroke. Importantly, many stroke survivors develop a chronic inflammatory response that may contribute to cognitive impairment, a common and debilitating sequela of stroke that is insufficiently studied and currently untreatable. 2-Hydroxypropyl-β-cyclodextrin (HPβCD) is an FDA-approved cyclic oligosaccharide that can solubilize and entrap lipophilic substances. The goal of the present study was to determine whether the repeated administration of HPβCD curtails the chronic inflammatory response to stroke by reducing lipid accumulation within stroke infarcts in a distal middle cerebral artery occlusion mouse model of stroke. To achieve this goal, we subcutaneously injected young adult and aged male mice with vehicle or HPβCD 3 times per week, with treatment beginning 1 week after stroke. We evaluated mice at 7 weeks following stroke using immunostaining, RNA sequencing, lipidomic, and behavioral analyses. Chronic stroke infarct and peri-infarct regions of HPβCD-treated mice were characterized by an upregulation of genes involved in lipid metabolism and a downregulation of genes involved in innate and adaptive immunity, reactive astrogliosis, and chemotaxis. Correspondingly, HPβCD reduced the accumulation of lipid droplets, T lymphocytes, B lymphocytes, and plasma cells in stroke infarcts. Repeated administration of HPβCD also preserved NeuN immunoreactivity in the striatum and thalamus and c-Fos immunoreactivity in hippocampal regions. Additionally, HPβCD improved recovery through the protection of hippocampal-dependent spatial working memory and reduction of impulsivity. These results indicate that systemic HPβCD treatment following stroke attenuates chronic inflammation and secondary neurodegeneration and prevents poststroke cognitive decline.SIGNIFICANCE STATEMENT Dementia is a common and debilitating sequela of stroke. Currently, there are no available treatments for poststroke dementia. Our study shows that lipid metabolism is disrupted in chronic stroke infarcts, which causes an accumulation of uncleared lipid debris and correlates with a chronic inflammatory response. To our knowledge, these substantial changes in lipid homeostasis have not been previously recognized or investigated in the context of ischemic stroke. We also provide a proof of principle that solubilizing and entrapping lipophilic substances using HPβCD could be an effective strategy for treating chronic inflammation after stroke and other CNS injuries. We propose that using HPβCD for the prevention of poststroke dementia could improve recovery and increase long-term quality of life in stroke sufferers. Copyright © 2022 Becktel et al.Note
Open access articleISSN
1529-2401PubMed ID
34819339Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1523/JNEUROSCI.0933-21.2021
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2022 Becktel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Related articles
- Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
- Authors: Hastings C, Liu B, Hurst B, Cox GF, Hrynkow S
- Issue date: 2022 Dec
- Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
- Authors: Hastings C, Vieira C, Liu B, Bascon C, Gao C, Wang RY, Casey A, Hrynkow S
- Issue date: 2019 Oct 21
- Neuroprotection by post-stroke administration of an oral formulation of angiotensin-(1-7) in ischaemic stroke.
- Authors: Bennion DM, Jones CH, Donnangelo LL, Graham JT, Isenberg JD, Dang AN, Rodriguez V, Sinisterra RDM, Sousa FB, Santos RAS, Sumners C
- Issue date: 2018 Jun
- 2-Hydroxypropyl-β-Cyclodextrin Treatment Induces Modest Immune Activation in Healthy Rhesus Macaques.
- Authors: Ortiz AM, Castello Casta F, Rahmberg A, Markowitz TE, Brooks K, Simpson J, Brenchley JM
- Issue date: 2023 Jul 27
- Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery.
- Authors: Nguyen TV, Crumpacker RH, Calderon KE, Garcia FG, Zbesko JC, Frye JB, Gonzalez S, Becktel DA, Yang T, Tavera-Garcia MA, Morrison HW, Schnellmann RG, Longo FM, Doyle KP
- Issue date: 2022 Feb